Extended indication Extension of indication for Nexpovio in combination with bortezomib and dexamethasone for the treatm
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Selinexor
Domain Oncology and Hematology
Reason of inclusion Indication extension
Main indication Multiple Myeloma
Extended indication Extension of indication for Nexpovio in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Proprietary name Nexpovio
Manufacturer Karyopharm
Mechanism of action Other
Route of administration Oral
Therapeutical formulation Coated tablet
Budgetting framework Intermural (MSZ)
Additional comments CRM1 nuclear export inhibitor.

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date May 2021
Expected Registration March 2022
Orphan drug Yes
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.